Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
quarterly or semiannual financial statement / - Increase in turnover by 5.7% to EUR 170.6 m after three quarters - Profit per share climbs from EUR 0.26 to EUR 0.86 - Renovation of the rehab area completed

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

9-month report


Ad hoc release according to § 15 WpHG Berlin 8th May 2008. Marseille-Kliniken AG (Prime Standard, ISIN DE  0007783003, MKA) was able to further increase its operating turnover by 5.7% to EUR 170.6 m in the first three quarters of the financial year 2007/2008 (previous  year  EUR 161.4 m). The EBIT improved from EUR 10.2 m to EUR 12.6 m. The EBITDAR  expanded from EUR 44.7 m to EUR 51.0 m. The unadjusted annual surplus increased from  EUR 3.1 m to currently EUR 10.4 m. For the profit per share this corresponds to  EUR 0.86, following EUR 0.26 in the comparison period  of  the  previous  year. The balanced equity is EUR 82.2 m (previous year:  EUR  66.3  m).   Thus  the  equity ratio could be expanded once more and is now at 32.6%. Due to the  latest  sale- and-lease-back transaction, the net debt of EUR 111.6 m  in  the  previous  year was reduced to currently EUR 69.8 m.

The return according to DVFA/SG, adjusted by the starting costs  of   care  costs and costs of idleness of rehabilitation facilities, decreased from EUR 9.2 m  to currently EUR 7.4 m. Although Rehabilitation was able to significantly  increase its return from EUR -1.1 m to EUR 0.8 m, the return in  Care  dropped  from  EUR 10.3 m to EUR 6.6 m. Therefore,  the  profit  per  share  according  to   DVFA/SG achieved EUR 0.60, following EUR 0.75 in the comparison period of  the  previous year. The adjusted EBITDAR was at EUR  45.9 m  at  the  end  of  the  reporting period, following EUR 49.9 m in the previous year.  The  adjusted  EBIT  reduced from EUR 16.7 m to currently EUR 12.5 m. The occupancy rate in the  consolidated group was increased from 89.9% to 92.5%.

The core segment  Care,  in  which  Marseille-Kliniken  represents   86%  of  the group's bed capacity, was able to continue gaining in turnover. With  EUR  132.7 m Marseille-Kliniken achieved an increase in turnover of EUR 8.9  m  during  the reporting period in this segment, as opposed to EUR  123.8  m  turnover  in  the period of the previous year. The occupancy rate was further  improved  with  the development of 92.8% in  the  previous  year  to  currently  93.4%.   The  return according to DVFA/SG reduced from EUR 10.3 m to currently EUR  6.6  m.  This  is essentially accounted for by high, unadjusted one-time investments in a  leading quality management system in Germany that incurred corresponding  expenses,  and the  related   roll-out  costs  for  the  broad  introduction  of  eLearning.  In addition, increased energy costs, higher advertising expenditures   and  advanced maintenance costs were a burden.

The positive development continued in Rehabilitation in  the  3rd   quarter.  The segment  has  completed  the  turnaround  and  is  no   longer    burdening    the consolidated operating  profits  this   financial  year  anymore.  This  way  the occupancy rate in the segment was able to be increased significantly from  76.8% in the previous year to 89.2%, with 1,283 beds. With EUR  37.9  m,  turnover in Rehabilitation was with the reduced capacity EUR 0.3 m over the previous  year's value of EUR 37.6 m  in  the  reporting  period.  In the  result  according  to DVFA/SG, with EUR 0.8 m once again  a   positive  contribution  was  able  to  be booked, after the value of the  previous  year's  EUR  -1.1  m.  Based  on  the division's successful renovation, the company maintains its intent to  sell  off Rehabilitation by selling the operating businesses as soon  as  the   uncertainty on the financial markets has calmed down.

The number of beds was increased to a total of 8,899 beds (+134) in the  current financial year. There are a further 4 locations with 600 beds  currently  under construction, and further bed capacities will be created in the Care segment  in the development of assisted living. In relation to this locations  have  already been secured in seven eastern  German  cities  for  the  purchase  of  operating companies for an additional 3000  flats  for  assisted  living,   which  will  be gradually taken over into the company in the coming financial years.

The company has corrected its forecast turnover by EUR 7.0 m to EUR 233.0 m  for the entire financial year 2007/2008. The main reason for this  is  the  delayed occupancy of expansion facilities in Care. In contrast,  the  EBIT  forecast  of EUR 24.0 and the results after tax of EUR 18.0 m remain  unchanged.  The  profit per share will therefore increase to EUR/share 1.48 in comparison  to  EUR/share 0.75 in the previous year.

End of the ad-hoc release

@@start.t2@@end of announcement                                                 euro adhoc

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar:

Further inquiry note:
If you have any questions, please contact:

Marseille-Kliniken AG                        
Axel Hölzer                                        
Alte Jakobstraße 79/80                      
10709 Berlin                                      
Tel.: +49 (0) 30 / 246 32-400          
Fax: +49 (0) 30 / 246 32-401                  ; ;

Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Tel.: +49 (0) 40 / 320 279 10
Fax: +49 (0) 40 / 320 279 114

Branche: Pharmaceuticals
ISIN:      DE0007783003
WKN:        778300
Index:    CDAX, Classic All Share, Prime All Share
Börsen:  Börse Frankfurt / regulated dealing/prime standard
              Börse Berlin / free trade
              Börse Stuttgart / free trade
              Börse Düsseldorf / free trade
              Börse Hamburg / regulated dealing

Weitere Meldungen: Marseille-Kliniken AG

Das könnte Sie auch interessieren: